145 related articles for article (PubMed ID: 2142873)
1. Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects.
Nicholson RI; Walker KJ; Bouzubar N; Wills RJ; Gee JM; Rushmere NK; Davies P
Ann N Y Acad Sci; 1990; 595():316-27. PubMed ID: 2142873
[TBL] [Abstract][Full Text] [Related]
2. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
3. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
4. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
6. Zoladex in advanced breast cancer.
Robertson JF; Nicholson RI; Walker KJ; Blamey RW
Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
[TBL] [Abstract][Full Text] [Related]
7. Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.
Nicholson RI; Walker KJ; McClelland RA; Dixon A; Robertson JF; Blamey RW
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):989-95. PubMed ID: 2149510
[TBL] [Abstract][Full Text] [Related]
8. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
[TBL] [Abstract][Full Text] [Related]
9. [Fulvestrant: a new agent in endocrine treatment for breast cancer].
Juretić A; Sarić N; Bisof V; Basić-Koretić M
Lijec Vjesn; 2006; 128(1-2):31-6. PubMed ID: 16640225
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
Klijn JG; Beex LV; Mauriac L; van Zijl JA; Veyret C; Wildiers J; Jassem J; Piccart M; Burghouts J; Becquart D; Seynaeve C; Mignolet F; Duchateau L
J Natl Cancer Inst; 2000 Jun; 92(11):903-11. PubMed ID: 10841825
[TBL] [Abstract][Full Text] [Related]
11. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
12. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
[TBL] [Abstract][Full Text] [Related]
13. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
14. Zoladex: therapeutic effects in postmenopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
[TBL] [Abstract][Full Text] [Related]
15. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
16. [New drugs in endocrine treatment of breast cancer].
Izuo M
Nihon Naibunpi Gakkai Zasshi; 1992 May; 68(5):538-49. PubMed ID: 1322843
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
[TBL] [Abstract][Full Text] [Related]
19. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
20. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
Lien EA; Johannessen DC; Aakvaag A; Lønning PE
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):541-3. PubMed ID: 1532904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]